Cutia Therapeutics (HKG:2487) posted a loss attributable to owners of 340.2 million yuan for 2025, narrowing from a loss of 433.8 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Loss per share at the pharmaceutical company came in at 1.03 yuan, compared with 1.41 yuan a year earlier.
Revenue rose to 336.2 million yuan from 279.6 million yuan in 2024.